Oric (ORIC) CFO Dominic Piscitelli Exercises Options and Sells Shares

What Happened
Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals (ORIC), exercised a total of 77,000 option shares on August 26, 2026 (52,000 at $4.36 and 25,000 at $6.00) for a combined exercise cost of $376,720, and sold 77,000 shares in an open-market transaction the same day for $13.69 each, generating $1,053,814 in gross proceeds. The sale was effected under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: August 26, 2026 (reported on Form 4 filed August 28, 2026 — within the typical 2-business-day reporting window).
• Exercises: 52,000 shares @ $4.36 = $226,720; 25,000 shares @ $6.00 = $150,000. (Code M = option exercise)
• Sale: 77,000 shares @ $13.69 = $1,053,814 (open market sale, Code S).
• Net cash (sale proceeds minus exercise cost): ~$677,094 (before taxes, fees and withholding).
• Footnotes: F2 — sales were made pursuant to a Rule 10b5-1 plan adopted May 26, 2026; F1 — filing notes 1,680 shares were acquired under the issuer’s 2020 Employee Stock Purchase Plan; F3 — option vesting schedule (25% vests Feb 1, 2024, then monthly 1/36th thereafter).
• Shares owned after the transactions are not specified in the provided excerpt of the filing.

Context
This was an option exercise followed by an immediate open-market sale of the resulting shares (commonly used to cover exercise cost and take gains). The listing of derivative dispositions at $0 simply reflects conversion of the options into common stock as part of the exercise. Because the sale was executed under a 10b5-1 plan, it likely followed pre-set instructions rather than being an ad-hoc decision.